Background and Purpose-Oxidative stress is an early response to cerebral ischemia and is likely to play an important role in the pathogenesis of cerebral ischemic injury. We sought to evaluate whether hyperacute plasma concentrations of biomarkers of oxidative stress, inflammation, and tissue damage predict infarct growth (IG). Methods-We prospectively measured plasma F2-isoprostane (F2-isoP), urinary 8-oxo-7,8-dihydro-2′-deoxyguoanosine, plasma oxygen radical absorbance capacity assay, high sensitivity C reactive protein, and matrix metalloproteinase 2 and 9 in consecutive patients with acute ischemic stroke presenting within 9 hours of symptom onset. Patients with baseline diffusion-weighted magnetic resonance imaging and follow-up diffusion-weighted imaging or computed tomographic scan were included to evaluate the final infarct volume. Baseline diffusion-weighted imaging volume and final infarct volume were analyzed using semiautomated volumetric method. IG volume was defined as the difference between final infarct volume and baseline diffusion-weighted imaging volume. Results-A total of 220 acute ischemic stroke subjects were included in the final analysis. One hundred seventy of these had IG. Baseline F2-isoP significantly correlated with IG volume (Spearman ρ=0.20; P=0.005) and final infarct volume (Spearman ρ=0.19; P=0.009). In a multivariate binary logistic regression model, baseline F2-isoP emerged as an independent predictor of the occurrence of IG (odds ratio, 2.57; 95% confidence interval, 1.37-4.83; P=0.007). In a multivariate linear regression model, baseline F2-isoP was independently associated with IG volume (B, 0.38; 95% confidence interval, 0.04-0.72; P=0.03). Conclusions-Elevated hyperacute plasma F2-isoP concentrations independently predict the occurrence of IG and IG volume in patients with acute ischemic stroke. If validated in future studies, measuring plasma F2-isoP might be helpful in the acute setting to stratify patients with acute ischemic stroke for relative severity of ischemic injury and expected progression.
S troke, with its important individual, social, and economic implications, has a major impact on our entire healthcare system. 1 Intravenous thrombolytic therapy with tissue-type plasminogen activator (t-PA) and endovascular therapies to achieve early recanalization are the only treatment proven to be beneficial in patients with acute ischemic stroke (AIS). 2, 3 The narrow therapeutic time window from symptom onset to treatment necessary for these therapies to salvage brain tissue and improve outcome continues to limit their broad application. 3 Attempts to extend this therapeutic window require a better decision-making protocol taking into account the pathophysiological aspects of infarct evolution. Therefore, there is a need for practical, time-efficient, and cost-effective measures that might be combined with neuroimaging to predict brain tissue outcome. Such measures would contribute to our understanding of stroke progression in humans and to the development of new therapeutic targets.
Clinical, genetic, and imaging variables strongly influence susceptibility to infarct growth (IG). [4] [5] [6] Experimental studies have demonstrated that free-radical-induced oxidative stress is one of the major contributors to the evolution of ischemic lesion and reperfusion-related brain tissue damage. 7 The crucial role of oxidative stress in infarct progression has been demonstrated by the reduction of infarct size through the inhibition of neuronal nitric oxide synthase in models of cerebral ischemia. 8 Despite this experimental evidence, data on oxidative stress biomarkers in the hyperacute phase of AIS in humans are limited, mainly because of the lack of valid measurable biomarkers.
9 F2-isoprostanes (F2-isoPs) are products of noncyclooxygenase-free radical-induced neuronal arachidonic acid peroxidation of membrane phospholipids and lipoproteins.
10 F2-isoPs are more stable, sensitive, and specific markers of oxidative stress-induced peroxidation than other biomarkers. 11, 12 They are easily quantifiable in plasma, urine, and cerebrospinal fluid in humans. 12 A previous study found an increase of plasma levels of F2-isoP in patients with AIS in the first 8 hours but not at 24 hours or later time points, suggesting oxidative stress activation early after stroke onset. 13 Several measures of total plasma antioxidant capacity, such as the oxidative radical absorbance capacity (ORAC) assay conducted in plasma ex vivo, may offer a complementary approach to the measurement of a broad spectrum of antioxidant micronutrients to assess oxidative stress and antioxidant system. 14, 15 Therefore, in this study, we sought to evaluate the role of hyperacute plasma levels of oxidative stress biomarkers in predicting IG and their association with IG volume (IGV) in patients with AIS and compare them to potential biomarkers of inflammation and tissue damage relevant to stroke.
Materials and Methods

Study Population and Clinical Data Collection
We prospectively enrolled patients presenting to 2 large academic medical centers with AIS within the first 9 hours of symptom onset. Patients with stroke on awakening and those with unwitnessed stroke onset were included only if the midway point between the last seen well and first seen abnormal times was within 9 hours. Patients with all degrees of stroke severity were included (National Institutes of Health Stroke Scale [NIHSS] score ≥1). Potential subjects were excluded from the study if they had hemorrhagic stroke; ischemic stroke because of probable vasculitis; endocarditis or venous infarction, transient ischemic attack (TIA) or stroke mimics; active infection (body temperature >38°C or white blood cells >15 th/mm 3 ); systemic inflammatory disorders; end-stage renal disease; end-stage liver disease; active metastatic malignancy at the time of stroke; a history of stroke within 30 days of the index stroke onset; myocardial infarction, major thromboembolic event, or major surgery within 30 days of stroke onset.
Informed consent was obtained from patients or their healthcare proxies. The study was approved by the local institutional review board at both centers.
Demographic (age, sex, race) and clinical data, including functional independence before the index stroke measured by modified Rankin Scale (mRS) score 0 to 1, vascular risk factors, medications, and vital signs, were recorded. Neurological severity at baseline and at 48 hours from symptom onset by using NIHSS score and outcome at 3 months by mRS score were assessed by staff certified in administering these scales by in-person or telephone interview of the patient or care giver. Blood samples for routine laboratory exams and biomarkers were performed at admission and at 48 hours (range, 36-60 hours). Stroke subtype was determined using the Causative Classification of Stroke System. 16, 17 
Laboratory Methods
Blood samples were collected at admission, <9 hours after stroke onset. To avoid delays in treatment, all blood samples from patients eligible for intravenous thrombolytic treatment were obtained after the treatment was initiated. Samples were analyzed by investigators blinded to clinical information.
Oxidative stress biomarkers F2-isoP, urinary 8-hydro-2′-deoxyguoanosine (8-OhdG), and plasma ORAC assay (total ORAC [ORAC TOTAL ] and perchloric acid ORAC [ORAC PCA ]) were evaluated in this study. Inflammatory and tissue damage biomarkers high sensitivity C reactive protein, matrix metalloproteinase (MMP) 2, and 9 were also evaluated.
For the quantification of F2-isoP, blood samples were collected in 10 mL EDTA tubes. Plasma was frozen at −80°C before processing. F2-isoP was quantified using an 8-Isoprostane Enzyme Immunoassay Kit (Cayman Chemical, Ann Arbor, MI). Laboratory methods used for the quantification of the other biomarkers are reported in the online-only Data Supplement.
Neuroimaging Analysis
Computed tomography and magnetic resonance imaging were performed on admission as part of the routine clinical stroke evaluation and based on clinical requirements at follow-up. Diffusion-weighted magnetic resonance imaging (DWI) performed at admission (within 24 hours of stroke onset) was used to asses baseline infarct volume. Both DWI and computed tomographic scans performed at 48 hours (with a range from 24 to 96 hours) from symptom onset were used as the measure of final infarct size; both of these modalities have been shown to define infarct limits reliably after 24 hours from stroke onset. 18 For the purpose of analysis, the patient cohort was divided in 2 groups based on the occurrence of IG (any IGV >0). IGV was defined as the final infarct volume (FIV) minus the baseline DWI volume (DWIV). Percentage IG was calculated by using the formula [(IGV/ baseline DWIV)×100]. Data on vessel stenosis/occlusion by computed tomographic or magnetic resonance angiography considered responsible for the index stroke, DWI and perfusion weighted magnetic resonance imaging mismatch volume (calculated as the volume of hypoperfused tissue measured by the mean transit time minus baseline DWIV), and symptomatic intracerebral hemorrhage (defined as any bleeding plus any neurological deterioration [NIHSS score ≥1] or that leads to death within 7 days) were also evaluated.
All volumetric data were processed using a validated semiautomated protocol. 19 The intraclass correlation coefficient for the volumetric lesion analysis was 0.99 for both DWIV and FIV. 20 All lesion volumes were corrected for differences in overall brain size using midsagittal cross-sectional intracranial area as a surrogate measure of the intracranial volume. 21 Imaging analyses were performed by experienced and trained physicians and neurologists blinded to clinical and laboratory data.
Statistical Analysis
Results for categorical variables are expressed as percentages, with proportions calculated by dividing the number of events by the total number of patients excluding missing or unknown cases. Results for continuous variables are expressed as medians (interquartile range) or means (±SD) for non-normal or normal variable distribution, respectively.
As appropriate, χ 2 or Fisher exact test and Student t test or MannWhitney U test were used to compare categorical and continuous variables between 2 groups. Because biomarkers and lesion volumes had a non-normal distribution, Spearman correlation coefficients (Spearman ρ) were derived to quantify the association between biomarkers and IGV. Natural logarithm transformation of continuous variables was used if appropriate, in case of non-normal distribution.
Multivariate binary logistic regression and linear regression modeling were used to adjust for the effects of potential confounders and
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to evaluate whether plasma biomarkers measured within 9 hours of symptom onset independently predicted IG occurrence and more specifically IGV. Covariates with a univariate association with IG or IGV at P≤0.10 were included in the relative multivariate models along with other potential predictors of IG independent of their univariate P value, including age, sex, NIHSS, and intravenous t-PA. All biomarkers were tested in the resultant multivariate model, independent of the significance of their univariate association with IG; tests were applied one by one to avoid model overfitting and spurious associations. Receiver operating characteristic curves and area under the curves were calculated to evaluate the predictive power of each of the significant independent predictors for IG. A 2-tailed P<0.05 was considered significant. All statistical analyses were performed with SPSS statistical package (SPSS Inc, Chicago, IL).
All supporting data are available within the article and its onlineonly Data Supplement.
Results
Overall, 525 patients were enrolled, of whom 489 had a final diagnosis of ischemic stroke. Thirty-six patients without ischemic stroke were excluded (20 TIAs, 14 nonstroke alternative diagnoses, 1 unknown diagnosis, and 1 patient who withdrew from the study after informed consent). Of 489 patients with AIS, 220 subjects had both baseline DWI and follow-up scans (DWI or computed tomography) and were included in the study ( Figure) . Compared with these, the remaining 269 patients without both baseline DWI and follow-up scans not included in the analysis differed for a lower functional independence (mRS, 0-1) before the index stroke ( Tables I, III , V, and VII in the online-only Data Supplement). Moreover, inclusion of other biomarkers (high sensitivity C reactive protein, MMP-2, MMP-9, ORAC TOTAL , ORAC PCA ) one by one, to avoid spurious associations and model overfitting, did not change the significance (P≤0.01, in each of these models) of F2-isoP in predicting IG. Similarly, by the addition of other imaging characteristic, such as vessel occlusion, to a further multivariate model including only relevant variables such as baseline lnF2-isoP, NIHSS, prior TIA, statin therapy, and lnDWIV, to avoid model overfitting, F2-isoP was confirmed as a significant independent predictor of IG occurrence (OR, 2.76; 95% CI, 1.01-7.53; P=0.048).
Baseline F2-isoP was also independently associated with IGV handled as a continuous dependent variable in a linear regression model (B, 0.38; 95% CI, 0.04-0.72; P=0.03; Table 4 
Discussion
In this study, we found that the hyperacute plasma levels of F2-isoP, a biomarker of oxidative stress-induced lipid peroxidation, is an independent predictor of the occurrence of IG and IGV in patients with AIS evaluated within 9 hours of symptom onset.
Several variables have been evaluated as correlates of susceptibility to IG in patients with AIS, [4] [5] [6] but no specific peripheral blood biomarker has been validated to date. An extraordinarily dynamic series of complex biochemical processes occurs at stroke onset. Oxidative stress, triggered in the early phase of ischemic brain injury, plays an important Values are medians (interquartile ranges). 8-OHdg indicates 8-hydro-2′-deoxyguoanosine; 8-OHdg_cr, 8-hydro-2′-deoxyguoanosine adjusted by creatinine (cr) levels; μmol TE/L, micromoles of Trolox equivalents per liter; F2-isoP, F2-isoprostane; hs-CRP, high sensitivity C reactive protein; MMP-2, metalloproteinase 2; MMP-9, metalloproteinase 9; and ORAC PCA , oxygen radical absorbance capacity (perchloric acid). BMI indicates body mass index; DBP, diastolic blood pressure; DWIV, diffusion-weighted imaging volume; FIV, final infarct volume; ICH, intracerebral hemorrhage; IQR, interquartile range; IV, intravenous; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; SD, standard deviation; SICH, symptomatic intracerebral hemorrhage; t-PA, tissue-type plasminogen activator; and TIA, transient ischemic attack. role in pathogenesis and evolution of the vascular lesions. 7, 13 In experimental models, high levels of free radicals and lipid peroxidation products have been associated with larger infarct volumes and more severe neurological impairment. 22 The reduction of infarct size induced through antioxidants in experimental studies has confirmed the fundamental role of oxidative stress in infarct progression. 7, 8, 23 Despite these experimental models, evidence is limited on oxidative stress biomarkers in the hyperacute phase of AIS in humans. Previous studies investigating biomarkers of oxidative stress observed higher levels of malondialdehyde and myeloperoxidase in patients with stroke compared with controls. [24] [25] [26] [27] Few studies focused on F2-isoPs, which are stable, sensitive, and specific markers of oxidative stress as compared with other biomarkers. 11, 25, 27 Moreover, they are easily measurable in plasma, urine, and cerebrospinal fluid. 12 Plasma levels of esterified and free F2-isoP increase within the first 8 hours of stroke onset, 13, 28 suggesting an early oxidative stress activation in patients with AIS. Therefore, F2-isoP can represent a good predictor of IG.
To our knowledge, this is the first study reporting F2-isoP levels as predictors of IG and IGV in patients with AIS. In our cohort, patients with IG had more severe disease. They had a larger baseline DWIV, a higher incidence of large-vessel occlusion and diabetes mellitus, and higher baseline blood glucose levels. These factors may play a role in the infarct evolution by promoting the progression of ischemia through complex mechanisms.
F2-isoP levels and their influence on the progression of ischemic brain damage could be affected by confounders. Interestingly, women were less likely to have IG although they usually tend to have worse outcome measures when we consider the natural stroke evolution. 29 This difference has to be viewed in context of mean (SD) age of our cohort patients which was relatively low (69.4±14.7), with men aged 68.1 years (±13.6) and women 71.3 years (±16.1). It seems that younger women have a lower likelihood of IG as compared with their age-matched male counterparts, 30 confirming a differential age-dependent worsening in tissue outcome in the 2 sexes. Moreover, older patients and patients with vessel occlusion were more likely to have a higher volume of IG. Premorbid history of TIA correlated with lower incidence of IG, suggesting a potential role of these transient events in ischemic preconditioning. Unfortunately, we do not have data on whether prior TIA occurred < or >30 days of the index stroke onset. Furthermore, intake of vitamin supplements before the index stroke had a protective effect leading to lower FIV, suggesting a role of these supplements as antioxidants. However, it should be taken into account that many variables can influence the extraordinary complexity of the antioxidant system including lifestyle habits, such as nutrition. Unfortunately, we did not have specific data on nutrition for this analysis.
To account for potential confounders, adjusted models in multivariate analyses were used. F2-isoP levels retained their ability to predict IG in these models emphasizing the fact that it is an independent predictor of IG.
Strengths of this study were the prospective design and the use of specific, well-defined, and precise exclusion criteria to minimize the impact of confounders. Blood samples were obtained in the early phase of stroke onset at the time when oxidative stress is likely to peak, providing valuable information about the pathophysiological aspects of ischemia progression. Finally, the large sample size allowed adjustment for variables that could potentially have an influence on the plasma levels of biomarkers and their association with IG.
Limitations of this study include retrospective analysis of the neuroimaging variables, which were not prespecified in the protocol. Advanced neuroimaging was obtained at the discretion of the treating stroke neurologist which might have led to patient selection bias. Moreover, baseline and follow-up images were obtained at different time points (within 24 hours and from 24 to 96 hours of symptom onset, respectively) based on clinical requirements which could lead to over-or underestimation of FIV. However, we did not find any significant differences in the time intervals from stroke onset or imaging-to-blood draw and from stroke onset to imaging between patients with and those without IG. Stroke severity in our cohort was moderate as measured by NIHSS which limits the generalizability of these findings to patients with severe strokes. In this analysis on IG, we had a wide range of missing values for the biomarkers investigated and measured at baseline: high sensitivity C reactive protein, 1.8% (4 of 220); MMP-2 and MMP-9, 6.4% (14 of 220); F2-isoP, 13% (29 of 220); ORAC TOTAL and ORAC PCA , 17.7% (39 of 220 each); 8-OHdG and 8-OHdG adjusted by creatinine (cr) levels, 58.6% (129 of 220 each). However, we think that most of these percentages can be considered acceptable for an analysis on biomarkers in the acute phase of stroke like this-particularly for those biomarkers that have been less investigated compared with others in the acute stroke in humans, such as F2-isoP. Moreover, no difference in the baseline characteristics was found between patients with missing values of F2-isoP at admission and those with no such missing values, except for a lower proportion of females (P=0.049) and prior stroke (P=0.034), a higher proportion of undetermined stroke (P=0.021), and a higher time interval stroke-to-imaging (median, 366 versus 293; P=0.002) in the group of patients with missing admission F2-isoP levels. Therefore, we are in the opinion that the percentage of missing values for F2-isoP did not impact the main results of our study. It is acknowledged that the percentage of missing values for 8-OHdG and 8-OHdG adjusted by creatinine (cr) levels is high; however, we think that the number of measurements for this biomarker that, to our knowledge, has never been studied in the acute phase of stroke in humans, can still be considered valuable to evaluate in an exploratory manner the presence of an association with IG. Specificity and sensitivity of F2-isoP are not optimal, therefore further specific studies with larger sample size and without the above mentioned limitations are needed to confirm the promise of this test for acute stroke.
Conclusions
Elevated hyperacute plasma F2-isoP concentrations independently predict the occurrence of IG and IGV in patients with AIS, suggesting a potential role of oxidative stress in promoting brain tissue injury and cell death. If validated in future studies, this biomarker could be helpful in understanding the pathophysiological aspects of ischemia and stroke progression in humans. This understanding will enable us to develop novel therapeutic targets. Moreover, these molecular markers could be adopted in clinical trials for patient selection to undergo acute stroke treatments and predicting outcomes.
